Results 231 to 240 of about 126,534 (277)

Opposite kinetics of L-leucine and L-phenylalanine induced insulin release studies with the perfused rat pancreas [PDF]

, 1972
Landgraf, R., Landgraf-Leurs, M. M. C., Schwarz, K., Scriba, Peter Christian   +3 more
core  

The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer's and Parkinson's Disease: A Literature Review of Clinical Trials. [PDF]

Life (Basel)
Pilśniak J, Węgrzynek-Gallina J, Bednarczyk B, Buczek A, Pilśniak A, Chmiela T, Jarosińska A, Siuda J, Holecki M.   +8 more
europepmc   +1 more source

Safety, feasibility, and dose‐dependent metabolic effects of endoscopic duodenal pulsed electric field therapy in adults with type 2 diabetes: Results from two multicentre proof‐of‐concept studies

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The duodenum plays a central role in metabolic regulation, influencing insulin sensitivity, and glucose homeostasis. In type 2 diabetes (T2D), structural and functional abnormalities of the duodenal mucosa (“diabetic duodenopathy”) are increasingly recognized as contributors to insulin resistance and dysglycaemia.
David N. O'Neal, Adrian Sartoretto, Bronte A. Holt, Barham K. Abu Dayyeh, Rhys Vaughan, Georgina Cameron, Sujievvan Chandran, Alexander J. Thompson, Howard McCollister, Paul Severson, Andrew C. Storm, Lian Cunningham, Elif I. Ekinci   +12 more
wiley   +1 more source

Effects of coaching with data management system intervention or usual care on glycemic control in patients with type 2 diabetes: A multicentre, randomised controlled trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Integrating a diabetes management system (DMS) and personal coaching in patient care may reduce the burden of type 2 diabetes (T2DM) on patients and help address the multifaceted challenges associated with diabetes management. This study aims to assess the impact of the DMS with online coaching in patients with T2DM on changes in HbA1c ...
Marlo Verket, Larissa F. Buitkamp, Niveditha Daneeza Dinesh Kanna, Andreas Thomas, Ralf Denger, Friedrich Petry, Oliver Schubert‐Olesen, Wolfgang Stütz, Jörg Simon, Monika Pihusch, Iris Dötsch, Gabriela Krob, Dietrich Tews, David Stolz, Dominik Bergis, Thorsten Lenthe, Frank Schmidt‐Mergenthaler, Elke Dahlmann, Kathrin Boehm, Malte Jacobsen, Dirk Müller‐Wieland, Julia Brandts   +21 more
wiley   +1 more source

Successful Use of Glucagon-Like Peptide-1 Receptor Agonist in a Patient With Recurrent Hypertriglyceridemia-Induced Pancreatitis. [PDF]

ACG Case Rep J
Guralwar C, Mitsuhashi S, Ashkar M, Chedid VG.   +3 more
europepmc   +1 more source

Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide.
Lanlan Chen, Paul Horn, Frank Tacke
wiley   +1 more source

RNA binding protein HuD regulates the biosynthesis of glucagon-like peptide 1 in intestinal L-cells. [PDF]

Biochem Biophys Rep
Han S, Jung M, Ryu S, Cha S, Tak H, Jeong SM, Lee EK.   +6 more
europepmc   +1 more source

Real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi‐site retrospective study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Despite the established efficacy of tirzepatide in randomised controlled trials, real‐world effectiveness data in Japanese patients remain limited. This study evaluated the real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes over 52 weeks.
Yusuke Minakata, Masaki Miura, Nobuhiro Nakatake, Masahiro Masuzawa   +3 more
wiley   +1 more source

Intractable Vomiting in the Setting of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist and Cannabis Usage. [PDF]

Cureus
DesRochers P, Kaiser L, Lee S, Perchetti GA, Lazarescu R.   +4 more
europepmc   +1 more source

Preoperative Glucagon-Like Peptide-1 Receptor Agonist Treatment to Allow Safe Laparoscopic Left Pancreatectomy in Extreme Obesity: The First Report. [PDF]

Case Rep Surg
Canali G, Herfeld G, Averous G, Baltzinger P, Addeo P.   +4 more
europepmc   +1 more source